Evidence map›Paper›PMID 36947289›Full record

ArticleDigestive diseases and sciences2023

Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.

Luis C Bertot, Gary P Jeffrey, Bastiaan de Boer, Zhengyi Wang, Yi Huang, George Garas, Gerry MacQuillan, Michael Wallace, Briohny W Smith, Leon A Adams

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Luis C BertotMedical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Gary P JeffreyMedical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Bastiaan de BoerDepartment of Anatomical Pathology, Pathwest, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Zhengyi WangMedical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Yi HuangMedical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
George GarasDepartment of Hepatology, Sir Charles Gairdner Hospital, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Gerry MacQuillanDepartment of Hepatology, Sir Charles Gairdner Hospital, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Michael WallaceMedical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Briohny W SmithDepartment of Hepatology, Sir Charles Gairdner Hospital, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia.
Leon A AdamsMedical School, University of Western Australia, QEII Medical Campus, Verdun St, Nedlands, WA, 6009, Australia. leon.adams@uwa.edu.au.ORCID http://orcid.org/0000-0002-3968-7909
The University of Western Australia · AUSir Charles Gairdner Hospital · AUPathwest Laboratory Medicine · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-invasive tests are widely used to diagnose fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), however, the optimal method remains unclear. We compared the accuracy of simple serum models, a serum model incorporating direct measures of fibrogenesis (Hepascore), and Fibroscan®, for detecting fibrosis in NAFLD.

methodsNAFLD patients undergoing liver biopsy were evaluated with Hepascore, NAFLD Fibrosis Score (NFS), FIB-4 and AST-platelet ratio index (APRI), with a subset (n = 131) undergoing Fibroscan®. Fibrosis on liver biopsy was categorized as advanced (F3-4) or cirrhosis (F4). Accuracy was determined by area under receiving operating characteristic curves (AUC). Indeterminate ranges were calculated using published cut-offs.

resultsIn 271 NAFLD patients, 83 (31%) had F3-4 and 47 (17%) cirrhosis. 6/131 (4%) had an unreliable Fibroscan®. For the detection of advanced fibrosis, the accuracy of Hepascore (AUC 0.88) was higher than FIB-4 (0.73), NFS (0.72) and APRI (0.69) (p < 0.001 for all). Hepascore had similar accuracy to Fibroscan® (0.80) overall, but higher accuracy in obese individuals (0.91 vs 0.80, p = 0.001). Hepascore more accurately identified patients with cirrhosis than APRI (AUC 0.85 vs 0.71, p = 0.01) and NFS (AUC 0.73, p = 0.01) but performed similar to FIB-4 and Fibroscan®. For the determination of F3-4, the proportion of patients in indeterminate area was lower for Hepascore (4.8%), compared to FIB-4 (42%), NFS (36%) and APRI (44%) (p < 0.001 for all).

conclusionsHepascore has greater accuracy and a lower indeterminate range than simple serum fibrosis tests for advanced fibrosis in NAFLD, and greater accuracy than Fibroscan® in obese individuals.

Indexed as

Non-alcoholic Fatty Liver DiseaseAspartate AminotransferasesBiomarkersBiopsyFibrosisHumansLiverLiver CirrhosisObesitySeverity of Illness IndexAspartate AminotransferasesBiomarkersDiagnosisElastographyLiver biopsyNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisNon-invasive fibrosis models

Identifiers

PMID36947289
PMCPMC10188580
OpenAlexW4353016387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.